Upon entry of this Amendment, the following listing of claims replace prior versions and listings of claims in the application.

Please cancel claims 2-19 and 21-22.

Please replace the pending claims with the following listing of claims:

Listing of Claims:

1. (Currently Amended) A peptide less than ~~280~~ 50 amino acids in length, wherein the peptide comprises the amino acid sequence of ~~SEQ ID NO: 5 or SEQ ID NO:6~~ SEQ ID NO:4 and inhibits c-jun amino terminal kinase (JNK) phosphorylation of a JNK targeted transcription factor selected from the group consisting of c-Jun, ATF2, and Elk1.

2. (Cancelled herein) ~~The peptide of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 4.~~

3. (Cancelled herein) ~~The peptide of claim 1, wherein the peptide is less than 50 amino acids in length.~~

a'

4. (Cancelled herein) ~~The peptide of claim 1, wherein the peptide binds c-jun amino terminal kinase (JNK).~~

5. (Cancelled herein) ~~The peptide of claim 1, wherein the peptide inhibits the activation of at least one JNK-targeted transcription factor when the peptide is present in a JNK expressing cell.~~

6. (Cancelled herein) ~~The peptide of claim 5, wherein the JNK-targeted transcription factor is selected from the group consisting of c-Jun, ATF2, and Elk1.~~

7. (Cancelled herein) ~~The peptide of claim 1, wherein the peptide alters a JNK effect when the peptide is present in a JNK expressing cell.~~

8. (Cancelled herein) ~~The peptide of claim 7, wherein the JNK-induced effect is selected from the group consisting of restenosis, oncogenic transformation, maturation and~~

~~differentiation of immune cells, proinflammatory cytokines, ionizing radiation as used in radiotherapy, ultraviolet light, free radicals, DNA damaging agents, chemotherapeutic drugs, ischemia, reperfusion, hypoxia, hypothermia, hyperthermia, apoptosis and response to stressful stimuli.~~

9. (Cancelled herein) ~~A chimeric peptide comprising a first domain and a second domain linked by a covalent bond, the first domain comprising a trafficking sequence, and the second domain comprising a JNK inhibitor sequence~~.

10. (Cancelled herein) ~~The peptide of claim 9, wherein the trafficking sequence comprises the amino acid sequence of SEQ ID NO: 9 or 10.~~

11. (Cancelled herein) ~~The peptide of claim 9, wherein the trafficking sequences augments cellular uptake of the peptide.~~

12. (Cancelled herein) ~~The peptide of claim 9, wherein the trafficking sequence directs nuclear localization of the peptide.~~

a!

13. (Cancelled herein) ~~The peptide of claim 9, wherein the trafficking sequence comprises the amino acid sequence of a human immunodeficiency virus TAT polypeptide.~~

14. (Cancelled herein) ~~The peptide of claim 9, wherein the JNK inhibitor sequence is~~
~~(a) less than 280 amino acids in length; and~~
~~(b) comprises the amino acid sequence of SEQ ID NO: 1.~~

15. (Cancelled herein) ~~The peptide of claim 9, wherein the JNK inhibitor sequence binds JNK.~~

16. (Cancelled herein) ~~The peptide of claim 9, wherein the JNK inhibitor sequence inhibits the activation of at least one JNK targeted transcription factor.~~

17. (Cancelled herein) ~~The peptide of claim 16, wherein the JNK targeted transcription factor is selected from the group consisting of c-Jun, ATF2, and Elk1.~~

18. (Cancelled herein) ~~The peptide of claim 9, wherein the JNK inhibitor sequence alters the JNK induced effects when introduced into a JNK expressing cell.~~

19. (Cancelled herein) ~~The peptide of claim 18, wherein the JNK induced effect is selected from the group consisting of restenosis, oncogenic transformation, maturation and differentiation of immune cells, proinflammatory cytokines, ionizing radiation as used in radiotherapy, ultraviolet light, free radicals, DNA damaging agents, chemotherapeutic drugs, ischemia, reperfusion, hypoxia, hypothermia, hyperthermia, apoptosis and response to stressful stimuli.~~

20. (Currently Amended) A ~~pharmaceutical~~ composition comprising ~~a~~ the peptide of claim 1, and a ~~pharmaceutically acceptable~~ carrier.

a'

21. (Cancelled herein) ~~The peptide of claim 9, wherein the trafficking sequence comprises the amino acid sequence of SEQ ID NO: 8.~~

22. (Cancelled herein) ~~The peptide of claim 38, wherein the JNK inhibitor sequence comprises the amino acid sequence of SEQ ID NO: 4.~~

23. (Currently Amended) A chimeric peptide comprising the amino acid sequence of SEQ ID NO:4 and SEQ ID NO:8, wherein said peptide inhibits c-jun amino terminal kinase (JNK) phosphorylation of a JNK targeted transcription factor selected from the group consisting of c-Jun, ATF2, and Elk1.

24. (Currently Amended) A peptide less than 50 amino acids in length comprising the amino acid sequence of SEQ ID NO:15, wherein said peptide inhibits c-jun amino terminal kinase (JNK) phosphorylation of a JNK targeted transcription factor selected from the group consisting of c-Jun, ATF2, and Elk1.

25. (New) A peptide consisting of the amino acid sequence of SEQ ID NO:4.

26. (New) A chimeric peptide comprising the amino acid sequence of SEQ ID NO:4 and SEQ ID NO:10 wherein said peptide inhibits c-jun amino terminal kinase (JNK) phosphorylation of a JNK targeted transcription factor selected from the group consisting of c-Jun, ATF2, and Elk1.

27. (New) A peptide consisting of the amino acid sequence of SEQ ID NO:15.

28. (New) A chimeric peptide consisting of the amino acid sequence of SEQ ID NO:4 and SEQ ID NO:10.

29. (New) A chimeric peptide consisting of the amino acid sequence of SEQ ID NO:4 and SEQ ID NO:8.

30. (New) A composition comprising the peptide of claim 25, 26, 27, 28 or 29 and a carrier.

31. (New) A composition comprising the peptide of claim 23 and a carrier.

32. (New) A composition comprising the peptide of claim 24 and a carrier.